サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1799171

血管周囲上皮細胞腫（PEComa）の世界市場

Perivascular Epithelioid Cell Tumors (PEComa)

出版日
ページ情報
英文 139 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.34円
血管周囲上皮細胞腫（PEComa）の世界市場
出版日: 2025年08月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 139 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

血管周囲上皮細胞腫（PEComa）の世界市場は2030年までに6,970万米ドルに達する見込み

2024年に5,420万米ドルと推定される血管周囲上皮細胞腫（PEComa）の世界市場は、2024年から2030年にかけてCAGR 4.3%で成長し、2030年には6,970万米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるPEComa治療は、CAGR 3.4%を記録し、分析期間終了時には4,140万米ドルに達すると予測されます。PEComa診断セグメントの成長率は、分析期間でCAGR 5.7%と推定されます。

米国市場は1,420万米ドルと推定、中国はCAGR4.3％で成長予測

米国の血管周囲上皮細胞腫（PEComa）市場は、2024年には1,420万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1,130万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは4.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.8％と3.8％と予測されています。欧州では、ドイツがCAGR 3.7%で成長すると予測されています。

世界の血管周囲上皮細胞腫（PEComa）市場- 主要動向と促進要因まとめ

なぜPEComaは腫瘍学的および希少腫瘍管理において重要性を増しているのか？

血管周囲上皮細胞腫（PEComa）は、メラノサイト系マーカーと平滑筋マーカーの共発現を特徴とする間葉系腫瘍のまれなグループを代表します。ほとんどの症例では組織学的に良性であるが、一部のPEComaは局所浸潤、再発および転移などの悪性挙動を示します。これらの腫瘍は、子宮、肺、消化管、腎臓、肝臓、軟部組織など様々な臓器に発生する可能性があり、診断と治療が分野横断的な課題となっています。

そのまれさと病理組織学的あいまいさにより、PEComaは伝統的に診断のジレンマとなってきました。しかしながら、免疫組織化学および分子プロファイリングの進歩-特にTSC1/TSC2遺伝子変異およびmTOR経路の活性化の同定-により、診断精度が著しく向上し、標的治療への道が開かれました。PEComaは現在、特に若年者や症候性の特徴を有する患者において、結節性硬化症複合体（TSC）に関連するより大きな腫瘍ファミリーの一部として認識されています。

腫瘍医および病理医の間で認識が高まるにつれて、PEComaはもはや他の平滑筋腫瘍または黒色腫様腫瘍と誤って分類されなくなりました。この動向は、特に3次がんセンターや肉腫紹介ネットワークにおいて、早期発見、適切な治療計画、および長期サーベイランスを改善しつつあります。集学的な腫瘍委員会は現在、手術、分子診断、および全身療法を包含するPEComa特異的な治療アルゴリズムを含むようになっています。

標的治療と分子的知見はPEComa治療をどのように変えているか？

PEComa治療における最も革新的な動向は、分子標的治療、特に哺乳類ラパマイシン標的（mTOR）シグナル伝達経路を標的とする治療へのシフトです。腫瘍抑制遺伝子であるTSC1とTSC2の変異は、mTORの構成的活性化につながり、治療の合理的な標的となっています。シロリムス、エベロリムス、テムシロリムスなどの薬剤は、もともとは免疫抑制剤または腎細胞がんの治療薬として開発されたものであるが、現在では進行したPEC腫の前治療または救済療法として再利用されています。

臨床症例報告および小規模試験では、転移性または切除不能のPEComa患者においてmTOR阻害薬による疾患の安定化および部分奏効が実証されています。これらの薬剤は、腫瘍の緩徐な増殖と低い有糸分裂指数のために限定的な有効性を示す従来の化学療法よりも好まれることが多いです。現在進行中の臨床試験では、mTORC1/mTORC2二重阻害剤の役割や、VEGFや免疫チェックポイント阻害剤との併用が、抵抗性に対処し治療の選択肢を広げるために検討されています。

HMB-45、Melan-A、SMA、デスミンを用いた免疫組織化学と次世代シークエンシング（NGS）の組み合わせにより、正確な腫瘍分類と治療指針が可能になりつつあります。リキッドバイオプシーと循環腫瘍DNA（ctDNA）解析は、治療反応をモニタリングし、微小残存病変を検出するための非侵襲的ツールとして登場するかもしれないです。これらの分子的アプローチは、一般的な腫瘍治療から個別化された希少腫瘍治療へとパラダイムを変えつつあります。

PEComaの管理パターンに影響を与えている医療環境と地域はどこか？

PEComaはその希少性から、主に高度診断および希少腫瘍委員会を備えた学術医療センター、肉腫専門クリニック、およびがん紹介病院で管理されます。ほとんどの症例は、無関係な愁訴に対する画像診断で、または線維腫、脂肪腫、子宮平滑筋腫と推定される腫瘤の切除後に最初に疑われます。診断の遅れは一般的であるが、MRI、PET-CT、および画像ガイド下生検の利用が増加しており、発見率は向上しています。

外科的切除は、限局性疾患の根治的治療の基礎です。しかし、悪性化の可能性、再発リスク、多発性（特にTSC患者）のため、長期間のサーベイランスが不可欠です。転移症例では、mTOR阻害剤の全身投与は、ゲノムプロファイリングが可能な総合がんセンターで開始されるのが一般的です。放射線療法は、特に外科的完全切除が不可能な一部の症例にのみ行われます。

発表された症例シリーズ、mTOR阻害剤へのアクセス、診断用分子ツールの面では、北米と欧州がリードしています。アジア太平洋では、特に日本と韓国で認知度と臨床報告が増加しています。ラテンアメリカとアフリカでは症例報告が限られているが、国際的な腫瘍登録と希少疾患ネットワークが、治療の提供、診断、治療の標準化におけるギャップを埋めるのに役立っています。

何が世界のPEComa治療市場の成長を促進しているのか？

PEComaの世界市場の成長は、疾患認知の向上、標的治療薬としてのmTOR阻害剤の出現、ゲノム診断の適用拡大、希少がんの専門医療ネットワークの開拓によって牽引されています。より多くの臨床医がPEComaの分子的背景と明確な治療ニーズを認識するようになるにつれて、早期診断と個別化治療が標準的な治療法となりつつあります。

mTOR阻害剤の規制当局による承認と適応外使用により、医師は侵攻性または切除不能なPEComaを管理するための効果的な選択肢を得た。希少腫瘍に対する抗がん剤の再利用に対する製薬企業の関心は、希少疾病用医薬品の指定、ファスト・トラック・パスウェイ、および患者アドボカシーの高まりに支えられて高まっています。さらに、希少腫瘍サーベイランス登録、NGSベースの診断アルゴリズム、集学的治療モデルの改善が、診断と治療の両面で成長を支えています。

分子医学が腫瘍学の中心になるにつれ、PEComaケアは超希少がんにおける個別化治療の可能性を例証しています。臨床医、研究者、バイオテクノロジー開発者の継続的な協力は、この謎めいた腫瘍群に対するアクセスを拡大し、誤診を減らし、長期的な転帰を改善する上で極めて重要です。

セグメント

タイプ（PEComa治療、PEComa診断）;エンドユース（病院エンドユース、診断センターエンドユース、その他エンドユース）

調査対象企業の例

  • Aadi Bioscience
  • AstraZeneca
  • Bayer
  • Celgene（Bristol Myers Squibb）
  • Daiichi Sankyo
  • Eisai Co., Ltd.
  • Exelixis
  • Ipsen
  • Loxo Oncology（Eli Lilly）
  • Merck & Co.
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Seagen
  • Sun Pharma
  • Taiho Pharmaceutical
  • Takeda
  • Turning Point Therapeutics
  • Bristol Myers Squibb

AIインテグレーション

検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革します。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP39182

Global Perivascular Epithelioid Cell Tumors (PEComa) Market to Reach US$69.7 Million by 2030

The global market for Perivascular Epithelioid Cell Tumors (PEComa) estimated at US$54.2 Million in the year 2024, is expected to reach US$69.7 Million by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. PEComa Treatment, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$41.4 Million by the end of the analysis period. Growth in the PEComa Diagnosis segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$14.2 Million While China is Forecast to Grow at 4.3% CAGR

The Perivascular Epithelioid Cell Tumors (PEComa) market in the U.S. is estimated at US$14.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$11.3 Million by the year 2030 trailing a CAGR of 4.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 3.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Perivascular Epithelioid Cell Tumors (PEComa) Market - Key Trends & Drivers Summarized

Why Are PEComas Gaining Significance in Oncologic and Rare Tumor Management?

Perivascular epithelioid cell tumors (PEComas) represent a rare group of mesenchymal tumors characterized by the co-expression of melanocytic and smooth muscle markers. Though histologically benign in most cases, some PEComas display malignant behavior, including local invasion, recurrence, and metastasis. These tumors can arise in various organs such as the uterus, lung, gastrointestinal tract, kidneys, liver, and soft tissues, making diagnosis and treatment a challenge across disciplines.

Their rarity and histopathological ambiguity have traditionally made PEComas a diagnostic dilemma. However, advances in immunohistochemistry and molecular profiling-particularly the identification of TSC1/TSC2 gene mutations and mTOR pathway activation-have significantly improved diagnostic accuracy and paved the way for targeted therapies. PEComas are now being recognized as part of a larger family of tumors associated with tuberous sclerosis complex (TSC), especially in younger individuals or those with syndromic features.

With rising awareness among oncologists and pathologists, PEComas are no longer misclassified as other smooth muscle or melanoma-like tumors. This trend is improving early identification, appropriate treatment planning, and long-term surveillance, particularly in tertiary cancer centers and sarcoma referral networks. Multidisciplinary tumor boards are now including PEComa-specific treatment algorithms that encompass surgery, molecular diagnostics, and systemic therapies.

How Are Targeted Therapies and Molecular Insights Reshaping PEComa Treatment?

The most transformative trend in PEComa treatment has been the shift toward molecularly targeted therapies, particularly those targeting the mammalian target of rapamycin (mTOR) signaling pathway. Mutations in TSC1 and TSC2, which are tumor suppressor genes, lead to constitutive activation of mTOR, making it a rational target for therapy. Drugs such as sirolimus, everolimus, and temsirolimus-originally developed as immunosuppressants or for renal cell carcinoma-are now repurposed as front-line or salvage therapies for advanced PEComas.

Clinical case reports and small-scale trials have demonstrated disease stabilization and partial responses with mTOR inhibitors in patients with metastatic or unresectable PEComas. These agents are often preferred over traditional chemotherapies, which have shown limited efficacy due to the tumor’s indolent growth and low mitotic index. Ongoing trials are exploring the role of dual mTORC1/mTORC2 inhibitors and combinations with VEGF or immune checkpoint inhibitors to address resistance and expand therapeutic options.

Immunohistochemistry using HMB-45, Melan-A, SMA, and desmin, combined with next-generation sequencing (NGS), is enabling precise tumor classification and therapy guidance. Liquid biopsy and circulating tumor DNA (ctDNA) analysis may emerge as non-invasive tools for monitoring treatment response and detecting minimal residual disease. These molecular approaches are shifting the paradigm from generic oncologic treatment to personalized rare tumor care.

Which Care Settings and Regions Are Influencing PEComa Management Patterns?

Due to their rarity, PEComas are predominantly managed in academic medical centers, sarcoma specialty clinics, and cancer referral hospitals equipped with advanced diagnostics and rare tumor boards. Most cases are initially suspected during imaging for unrelated complaints or following resection of masses presumed to be fibromas, lipomas, or uterine leiomyomas. Delayed diagnosis is common, but increasing use of MRI, PET-CT, and image-guided biopsies is improving detection rates.

Surgical resection remains the cornerstone of curative treatment in localized disease. However, due to potential malignant transformation, recurrence risk, and multifocality (especially in TSC patients), long-term surveillance is essential. In metastatic cases, systemic mTOR inhibitors are typically initiated at comprehensive cancer centers with access to genomic profiling. Radiotherapy is reserved for select cases, particularly where complete surgical resection is not feasible.

North America and Europe lead in terms of published case series, access to mTOR inhibitors, and diagnostic molecular tools. Asia-Pacific is seeing increasing awareness and clinical reporting, especially from Japan and South Korea. Latin America and Africa have limited case documentation, but international tumor registries and rare disease networks are helping bridge gaps in care delivery, diagnosis, and treatment standardization.

What Is Driving Growth in the Global PEComa Treatment Market?

The growth in the global PEComa market is driven by improved disease recognition, the emergence of mTOR inhibitors as targeted therapies, the expanding application of genomic diagnostics, and the development of specialized care networks for rare cancers. As more clinicians become aware of the molecular underpinnings and distinct treatment needs of PEComa, earlier diagnosis and tailored therapy are becoming standard practice.

Regulatory approvals and off-label use of mTOR inhibitors have given physicians effective options for managing aggressive or unresectable PEComas. Pharmaceutical interest in repurposing cancer drugs for rare tumors is increasing, supported by orphan drug designations, fast-track pathways, and growing patient advocacy. Furthermore, improvements in rare tumor surveillance registries, NGS-based diagnostic algorithms, and multidisciplinary care models are supporting growth in both diagnosis and treatment.

As molecular medicine becomes central to oncology, PEComa care exemplifies the potential for personalized therapy in ultra-rare cancers. The continued collaboration between clinicians, researchers, and biotech developers will be crucial in expanding access, reducing misdiagnosis, and improving long-term outcomes for this enigmatic tumor family.

SCOPE OF STUDY:

The report analyzes the Perivascular Epithelioid Cell Tumors (PEComa) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (PEComa Treatment, PEComa Diagnosis); End-Use (Hospitals End-Use, Diagnostic Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

  • Aadi Bioscience
  • AstraZeneca
  • Bayer
  • Celgene (Bristol Myers Squibb)
  • Daiichi Sankyo
  • Eisai Co., Ltd.
  • Exelixis
  • Ipsen
  • Loxo Oncology (Eli Lilly)
  • Merck & Co.
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Seagen
  • Sun Pharma
  • Taiho Pharmaceutical
  • Takeda
  • Turning Point Therapeutics
  • Bristol Myers Squibb

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Perivascular Epithelioid Cell Tumors (PEComa) - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Rare Soft Tissue Tumors Throws the Spotlight on PEComa Diagnosis and Therapy
    • Increased Use of Immunohistochemical and Molecular Profiling Drives Accurate PEComa Identification
    • Expansion of Targeted Oncology Therapies Strengthens Business Case for PEComa-Specific Treatment Development
    • FDA Approvals for mTOR Inhibitors Propel Market for Targeted PEComa Management
    • Growth in Rare Cancer Registries Enhances Data Availability and Clinical Insights on PEComa
    • Adoption of Next-Generation Sequencing in Rare Tumor Diagnosis Fuels Personalized Therapy Development
    • Academic Research Consortia Drive Multi-Institutional Trials on PEComa Treatment Efficacy
    • Rising Awareness Among Oncologists Expands Early Diagnosis and Intervention Rates
    • Global Clinical Trial Activity for PEComa Therapeutics Expands Addressable Market for Biopharma Firms
    • Advances in Immuno-Oncology Support Development of Novel Approaches for PEComa
    • Integration of AI in Tumor Classification Enhances Diagnostic Accuracy for Rare Malignancies
    • Growing Patient Advocacy Networks Drive Research Funding and Diagnostic Tool Accessibility
    • Surge in Orphan Drug Designation Programs Spurs Innovation in PEComa Drug Pipelines
    • Standardization of Histopathologic Criteria Strengthens Diagnostic Consistency Across Centers
    • Improved Access to PET-CT and MRI Imaging Enhances Detection of PEComa Metastasis
    • Biomarker-Driven Clinical Decision Support Tools Enable Tailored PEComa Treatment Regimens
    • Collaborative Rare Tumor Repositories Promote Data Sharing and Therapeutic Advancements
    • Regulatory Incentives for Orphan Oncology Drugs Accelerate Market Entry for PEComa Therapies
    • Emergence of Real-World Evidence Platforms Enhances Treatment Evaluation in Low-Incidence Cancers
    • Precision Oncology Platforms Expand Companion Diagnostic Development for PEComa Patient Stratification
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Perivascular Epithelioid Cell Tumors (PEComa) Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for PEComa Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for PEComa Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for PEComa Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for PEComa Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Diagnostic Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Perivascular Epithelioid Cell Tumors (PEComa) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Type - PEComa Treatment and PEComa Diagnosis - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Type - Percentage Breakdown of Value Sales for PEComa Treatment and PEComa Diagnosis for the Years 2025 & 2030
    • TABLE 16: USA Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 17: USA 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • CANADA
    • TABLE 18: Canada Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Type - PEComa Treatment and PEComa Diagnosis - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 19: Canada 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Type - Percentage Breakdown of Value Sales for PEComa Treatment and PEComa Diagnosis for the Years 2025 & 2030
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Canada 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • JAPAN
    • Perivascular Epithelioid Cell Tumors (PEComa) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 22: Japan Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Type - PEComa Treatment and PEComa Diagnosis - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 23: Japan 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Type - Percentage Breakdown of Value Sales for PEComa Treatment and PEComa Diagnosis for the Years 2025 & 2030
    • TABLE 24: Japan Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Japan 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • CHINA
    • Perivascular Epithelioid Cell Tumors (PEComa) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Type - PEComa Treatment and PEComa Diagnosis - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 27: China 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Type - Percentage Breakdown of Value Sales for PEComa Treatment and PEComa Diagnosis for the Years 2025 & 2030
    • TABLE 28: China Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 29: China 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • EUROPE
    • Perivascular Epithelioid Cell Tumors (PEComa) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 30: Europe Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 31: Europe 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Type - PEComa Treatment and PEComa Diagnosis - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Type - Percentage Breakdown of Value Sales for PEComa Treatment and PEComa Diagnosis for the Years 2025 & 2030
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Europe 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • FRANCE
    • Perivascular Epithelioid Cell Tumors (PEComa) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 36: France Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Type - PEComa Treatment and PEComa Diagnosis - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 37: France 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Type - Percentage Breakdown of Value Sales for PEComa Treatment and PEComa Diagnosis for the Years 2025 & 2030
    • TABLE 38: France Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: France 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • GERMANY
    • Perivascular Epithelioid Cell Tumors (PEComa) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 40: Germany Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Type - PEComa Treatment and PEComa Diagnosis - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Germany 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Type - Percentage Breakdown of Value Sales for PEComa Treatment and PEComa Diagnosis for the Years 2025 & 2030
    • TABLE 42: Germany Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Germany 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Type - PEComa Treatment and PEComa Diagnosis - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Italy 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Type - Percentage Breakdown of Value Sales for PEComa Treatment and PEComa Diagnosis for the Years 2025 & 2030
    • TABLE 46: Italy Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Italy 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • UNITED KINGDOM
    • Perivascular Epithelioid Cell Tumors (PEComa) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 48: UK Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Type - PEComa Treatment and PEComa Diagnosis - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 49: UK 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Type - Percentage Breakdown of Value Sales for PEComa Treatment and PEComa Diagnosis for the Years 2025 & 2030
    • TABLE 50: UK Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: UK 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 52: Rest of Europe Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Type - PEComa Treatment and PEComa Diagnosis - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Rest of Europe 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Type - Percentage Breakdown of Value Sales for PEComa Treatment and PEComa Diagnosis for the Years 2025 & 2030
    • TABLE 54: Rest of Europe Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Rest of Europe 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Perivascular Epithelioid Cell Tumors (PEComa) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Type - PEComa Treatment and PEComa Diagnosis - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Type - Percentage Breakdown of Value Sales for PEComa Treatment and PEComa Diagnosis for the Years 2025 & 2030
    • TABLE 58: Asia-Pacific Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Asia-Pacific 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 60: Rest of World Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by Type - PEComa Treatment and PEComa Diagnosis - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Rest of World 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by Type - Percentage Breakdown of Value Sales for PEComa Treatment and PEComa Diagnosis for the Years 2025 & 2030
    • TABLE 62: Rest of World Recent Past, Current & Future Analysis for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Rest of World 6-Year Perspective for Perivascular Epithelioid Cell Tumors (PEComa) by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2025 & 2030

IV. COMPETITION